Combined with the stat you mentioned, it's a strange one. Maybe I'm looking at it wrong, but there's barely any physicians receiving above $50k in payments, so the biggest impact pharma payments have made is around a 5 % difference in prescribing. Looking at the variation at around $0-$10k, 5 % seems like a tiny change, since you have docs prescribing anywhere from 0 % and 80 %. Something else is driving it, my guess would be good personal relationships with sales reps? In that case, focusing on limiting that would have a much better impact on fixing the issue.
The big variation could also be something completely innocent like trust in a specific brand due to experience in the clinic, etc. Perhaps someone more knowledgeable can chime in.
Combined with the stat you mentioned, it's a strange one. Maybe I'm looking at it wrong, but there's barely any physicians receiving above $50k in payments, so the biggest impact pharma payments have made is around a 5 % difference in prescribing. Looking at the variation at around $0-$10k, 5 % seems like a tiny change, since you have docs prescribing anywhere from 0 % and 80 %. Something else is driving it, my guess would be good personal relationships with sales reps? In that case, focusing on limiting that would have a much better impact on fixing the issue.
The big variation could also be something completely innocent like trust in a specific brand due to experience in the clinic, etc. Perhaps someone more knowledgeable can chime in.